

**The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine**

Ziad Julier<sup>a,1</sup>, Mikaël M. Martino<sup>a,b,1</sup>, Alexandre de Titta<sup>a</sup>, Laura Jeanbart<sup>a</sup>, Jeffrey A. Hubbell<sup>a,c,d,e,\*</sup>


Author affiliations: <sup>a</sup> Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland; <sup>b</sup> World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan; <sup>c</sup> Institute for Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland; <sup>d</sup> Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA; <sup>e</sup> Materials Science Division, Argonne National Laboratory, Argonne, IL 60439, USA

<sup>1</sup> These authors contributed equally


\* To whom correspondence should be addressed, [jeffrey.hubbell@epfl.ch](mailto:jeffrey.hubbell@epfl.ch) or [jhubbell@uchicago.edu](mailto:jhubbell@uchicago.edu)

## Supporting Information

a



b



**Fig. S1** (a) SDS-PAGE analysis of the 6 different FNIII EDA-containing FN fragments produced. (b) SDS-PAGE of FNIII 9-10-EDA-12-13-14 with or without prior incubation with thrombin or plasmin or a cocktail of MMP-2, MMP-3 and MMP-9